A Prospective Study of Detection of Pancreatic Carcinoma by Combined Plasma K -ras Mutations and Serum CA19-9 Analysis

Feng, Dan; Zhang, Sheng-Dao; Han, Tao; Yu, Jiang; Lei, Ruo-qing; Zurong, Yuan; Wang, Xuezhi

doi:10.1097/00006676-200211000-00003

Cited by 46 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, occurrence of mutations in samples analysed in our study can hardly be compared with incidences found by other investigators (Mulcahy et al, 1998;Castells et al, 1999;Dianxu et al, 2002;Maire et al, 2002). The percentages of plasma samples with mutated Ki-ras gene found to date in the existing studies differ in a wide range of 27 -81%, which might reflect collection of samples at different tumour stages and various sensitivities of the assays for detection of Ki-ras point mutations.…”

contrasting

confidence: 56%

“…The percentages of plasma samples with mutated Ki-ras gene found to date in the existing studies differ in a wide range of 27 -81%, which might reflect collection of samples at different tumour stages and various sensitivities of the assays for detection of Ki-ras point mutations. Dianxu et al (2002) tested 37 of 41 patients (90.2%) with pancreatic cancer positive when plasma Ki-ras mutation analysis was combined with elevated CA 19-9 serum levels (437 Units ml À1 ). In our study, we detected Ki-ras mutant alleles only in four out of 10 patients with high CA 19-9 levels.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes

et al. 2005

View full text Add to dashboard Cite

In the present study, we combined the PCR-clamping approach with melting curve analysis using mutant specific hybridisation probes and wild-type specific peptide nucleic acids (PNAs) to determine the genotypes of the most frequent point mutation in codon 12 of the proto-oncogene Ki-ras in tissue and plasma samples of patients with pancreatic cancer. The sensitivity of our assay was 1 -5 Â 10 À5 . The melting curve analysis of tissue samples of four patients revealed two valine mutations, one none-valine mutation and one wild-type sequence. Ki-ras alterations were found in 28% of DNAs (18 out of 64) of nonrelated plasma samples of 10 patients with ductal adenocarcinoma of the pancreas. The valine mutation was the predominantly detected gene alteration (83%). Out of ten patients investigated, four patients (40%) became positive during clinical observation with respect to Ki-ras mutation. All four patients exhibited progressive disease and high levels of tumour marker CA 19-9. In conclusion, the one-step procedure discribed may be a useful clinical tool for analysing Ki-ras point mutations in tissue and plasmas samples. In addition, this method can be adapted for simultanous detection of multiple mutations and quantitation.

show abstract

contrasting

confidence: 56%

mentioning

confidence: 99%

Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Mulcahy et al have found a K-ras mutation in plasma DNA in patients who were diagnosed with pancreatic cancer 5 to 14 months later and did not find these alterations in patients with chronic pancreatitis or healthy subjects [83]. The detection of K-ras mutation in plasma DNA and an increase in the CA 19-9 tumor marker are independent events in pancreatic cancer and test sensitivity reached 90% when both tests were combined [84]. A longitudinal prospective study by Gormally et al has shown that detection of KRAS2 and p53 mutations in plasma of healthy individuals is associated with an increased risk of bladder cancer [85].…”

Section: Cirdna Mutations In Different Cancersmentioning

confidence: 99%

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Vlassov¹,

Laktionov²,

Rykova³

2010

CMM

View full text Add to dashboard Cite

Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.

show abstract

“…However, plasma KRAS mutation was also detected in two patients with chronic pancreatitis. Dianxu et al (2002) tried to establish the diagnostic value of codon 12 KRAS mutations in plasma combined with serum CA19-9 in 58 consecutive patients with a suspected pancreatic mass. Forty-one patients were subsequently diagnosed with pancreatic adenocarcinoma.…”

Section: Pancreatic Cancermentioning

confidence: 99%

Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours

Aung

Board

Ellison

et al. 2010

HUGO J

View full text Add to dashboard Cite

Genetic alterations can determine the natural history of cancer and its treatment response. With further advances in DNA sequencing technology, multiple novel genetic alterations will be discovered which could be exploited as prognostic, predictive and pharmacodynamic biomarkers in the development and use of cancer therapeutics. As such, the importance in clinical practice of efficient and robust somatic mutation testing in solid tumours cannot be overemphasized in the current era of personalized medicine. However, significant challenges remain regarding the testing of genetic biomarkers in clinical practice. Reliance on archived formalin fixed, paraffin embedded tumour, obtained from diagnostic biopsies, for testing somatic genetic alterations could restrict the scientific community in asking relevant questions about a patient's cancer biology. Problems inherent with using formalin fixed, archival tissue are well recognized and difficult to resolve. It could be argued that to achieve rapid and efficient incorporation of genetic biomarkers into clinical practice, somatic mutation testing in cancer patients should be simpler, less invasive using a readily available clinical sample, whilst maintaining robustness and reproducibility. In this regard, use of circulating free DNA (cfDNA) from plasma or serum as an alternative and/or additional source of DNA to test cancer specific genetic alterations is an attractive proposition. In light of encouraging results from recent studies, this mini review will discuss the current role and future potential of somatic mutation testing from circulating or cell free DNA derived from the blood of patients with solid tumours.

show abstract

A Prospective Study of Detection of Pancreatic Carcinoma by Combined Plasma K -ras Mutations and Serum CA19-9 Analysis

Abstract: The results indicate that plasma K mutation analysis combined with serum CA19-9 determination could detect the majority of cases of pancreatic carcinoma.

Cited by 46 publications

References 20 publications

Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes

Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours

Contact Info

Product

Resources

About